Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records

Clinical Cardiology

Volumn 36, Issue 8, 2013, Pages 486-491

  Cross, Deanna S ^a   McCarty, Catherine A ^b   Steinhubl, Steven R ^c   Carey, David J ^c,d   Erlich, Porat M ^c  

^a MARSHFIELD CLINIC   (United States)

^b DIVISION OF RESEARCH   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d WEIS CENTER FOR RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SIMULATION; VALIDATION PROCESS;

AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INCIDENCE; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; UNITED STATES;

EID: 84882266047     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22146     Document Type: Article

References (36)

1. Lloyd-Jones DM, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121: e1-e170.
2. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2-e220.
3. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force. Ann Intern Med. 2009; 151: 496-507.
4. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002; 106: 3143-3421.
5. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837-1847.
6. Brekke M, Straand J,. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational study. BMC Public Health. 2011; 11: 144.
7. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290: 898-904.
8. Kullo IJ, Cooper LT,. Early identification of cardiovascular risk using genomics and proteomics. Nat Rev Cardiol. 2010; 7: 309-317.
9. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol. 2010; 105: 1284-1288.
10. Rana JS, Gransar H, Wong ND, et al. Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events. Am J Cardiol. 2012; 109: 1449-1453.
11. Wilson PW,. Prediction of cardiovascular disease events. Cardiol Clin. 2011; 29: 1-13.
12. Hlatky MA,. Framework for evaluating novel risk markers. Ann Intern Med. 2012; 156: 468-469.
13. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119: 2408-2416.
14. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012; 156: 438-444.
15. Geisinger's MyCode project: the link to personalized medicine [press release]. Danville, PA: Geisinger Health System; February 17, 2009. https://webapps.geisinger.org/ghsnews/articles/GeisingersMyCodeprojectth3000. html. Accessed December 4, 2012.
16. McCarty CA, Peissig P, Caldwell MD, et al. The Marshfield Clinic Personalized Medicine Research Project: 2008 scientific update and lessons learned in the first 6 years. Personalized Med. 2008; 5: 529-542.
17. McCarty CA, Wilke RA, Giampietro PF, et al. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Med. 2005; 2: 49-79.
18. Wilke RA, Berg RL, Peissig P, et al. Use of an electronic medical record for the identification of research subjects with diabetes mellitus. Clin Med Res. 2007; 5: 1-7.
19. Elkan C,. Evaluating classifiers. http://cseweb.ucsd.edu/ &thksimelkan/250B/classifiereval.pdf. Published January 20, 2012. Accessed December 4, 2012.
20. Forman G, Scholz M,. Apples to apples in cross-validation studies: pitfalls in classifier performance measurement. SIGKDD Explorations. 2010;1:49-57. http://www.hpl.hp.com/techreports/2009/HPL-2009-359.pdf. Accessed December 4, 2012.
21. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-845.
22. Pathak J, Pan H, Wang J, et al. Evaluating phenotypic data elements for genetics and epidemiological research: experiences from the eMERGE and PhenX Network projects. AMIA Summits Transl Sci Proc. 2011; 2011: 41-45.
23. Pathak J, Wang J, Kashyap S, et al. Mapping clinical phenotype data elements to standardized metadata repositories and controlled terminologies: the eMERGE Network experience. J Am Med Inform Assoc. 2011; 18: 376-386.
24. Magid DJ, Gurwitz JH, Rumsfeld JS, et al. Creating a research data network for cardiovascular disease: the CVRN. Exp Rev Cardiovasc Ther. 2008; 6: 1043-1045.
25. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996; 49: 223-233.
26. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995; 5: 278-285.
27. National Institutes of Health, National Heart, Lung, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. http://www.nhlbi.nih.gov/resources/docs/06a-ip-chtbk.pdf. Published May 2006. Accessed December 4, 2012.
28. Shurtleff D,. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 16-year follow-up. In: Kannel W, Gordon T, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Monograph section 26. Washington, DC: US Department of Health, Education, and Welfare, US Government Printing Office; 1970:1-26.
29. Huffman MD, Capewell S, Ning H, et al. Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation. 2012; 125: 2595-2602.
30. Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012; 344: e3318.
31. Tzoulaki I, Liberopoulos G, Ioannidis JP,. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009; 302: 2345-2352.
32. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297: 611-619.
33. Nandish S, Wyatt J, Bailon O, et al. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011; 108 (3 suppl): 42B-51B.
34. Tattersall MC, Gangnon RE, Karmali KN, et al. Women up, men down: the clinical impact of replacing the Framingham Risk Score with the Reynolds Risk Score in the United States population. PLoS One. 2012; 7: e44347.
35. Berger JS, Jordan CO, Lloyd-Jones D, et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010; 55: 1169-1177.
36. Capewell S, Ford ES, Croft JB, et al. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ. 2010; 88: 120-130.